VolitionRx (NYSE:VNRX) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a report released on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $5.00 target price on the stock.

Several other equities analysts also recently weighed in on the company. HC Wainwright initiated coverage on VolitionRx in a research note on Tuesday, April 8th. They issued a "buy" rating and a $2.50 price objective for the company. StockNews.com started coverage on VolitionRx in a research report on Tuesday. They issued a "sell" rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $3.33.

VolitionRx Stock Performance

VNRX traded down $0.01 on Wednesday, hitting $0.48. 120,723 shares of the company were exchanged, compared to its average volume of 175,601. The business's fifty day moving average is $0.53 and its 200 day moving average is $0.60. VolitionRx has a fifty-two week low of $0.42 and a fifty-two week high of $0.91. The firm has a market capitalization of $47.87 million, a P/E ratio of -1.32 and a beta of 1.15.

Insider Activity

In other news, CEO Cameron John Reynolds acquired 181,818 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $0.55 per share, with a total value of $99,999.90. Following the completion of the acquisition, the chief executive officer now directly owns 2,299,222 shares in the company, valued at $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 12.80% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC acquired a new position in VolitionRx in the fourth quarter worth $29,000. Millennium Management LLC bought a new position in shares of VolitionRx in the 4th quarter worth about $36,000. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after buying an additional 28,579 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock valued at $439,000 after buying an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. grew its position in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after buying an additional 1,481,000 shares during the last quarter. Institutional investors and hedge funds own 8.09% of the company's stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.